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Abstract
Background: Despite many attempts to establish pre-treatment prognostic markers to understand the clinical biology of
esophageal adenocarcinoma (EAC), validated clinical biomarkers or parameters remain elusive. We generated and analyzed
tumor transcriptome to develop a practical biomarker prognostic signature in EAC.
Methodology/Principal Findings: Untreated esophageal endoscopic biopsy specimens were obtained from 64 patients
undergoing surgery and chemoradiation. Using DNA microarray technology, genome-wide gene expression profiling was
performed on 75 untreated cancer specimens from 64 EAC patients. By applying various statistical and informatical methods
to gene expression data, we discovered distinct subgroups of EAC with differences in overall gene expression patterns and
identified potential biomarkers significantly associated with prognosis. The candidate marker genes were further explored
in formalin-fixed, paraffin-embedded tissues from an independent cohort (52 patients) using quantitative RT-PCR to
measure gene expression. We identified two genes whose expression was associated with overall survival in 52 EAC patients
and the combined 2-gene expression signature was independently associated with poor outcome (P,0.024) in the
multivariate Cox hazard regression analysis.
Conclusions/Significance: Our findings suggest that the molecular gene expression signatures are associated with
prognosis of EAC patients and can be assessed prior to any therapy. This signature could provide important improvement
for the management of EAC patients.
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Introduction
Esophageal adenocarcinoma (EAC) is one of high mortality
cancers in the West and having a 5-year survival rate of less than
10% [1,2]. The occurrence of EAC has increased over the past 20
years [3]. In the United States, it was projected that there were more
than 14,000 deaths from EAC in 2009 [4]. The reason for this
increase in EAC is unknown. Several studies have shown that at
least 95% of EAC cases arise from the metaplastic condition known
as Barrett’s esophagus, which is caused by gastroesophageal reflux
disease [5,6]. Surgery is the best curative treatment option but only
a small fraction of EAC patients benefit because many patients still
suffer from recurrence within 2 years after curative treatment [2,7].
Despite continual efforts to preoperatively select patients who are
likely to benefit from potentially curative surgery, the current
staging system, which uses TNM stage and lymph node status, has
shown limited success in predicting the duration of overall survival
(OS) or recurrence-free survival (RFS) in EAC patients [8].
Gene expression profiling studies of various cancers have discovered
consistent gene expression patterns associated with pathological or
clinical phenotype, elucidating subtypes of cancer previously uniden-
tified with conventional technologies [9–13]. Therefore, we investigat-
ed the possibility that gene-expression variations found in EAC biopsy
samples, obtained prior to administering any therapy, would permit the
identification of distinct subclasses of EAC patients with different
prognoses. Our goal was to identify a subgroup of patients who do not
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derive much benefit from combined modality therapy and have a very
poor prognosis. Our results revealed three subclasses of EAC patients
characterized by significant differences in gene expression that
correlated with prognosis. We also identified expression profiles for a
limited number of genes that accurately predicted prognosis and
explored the possibility for the use of the expression signature as
prognostic marker.
Methods
Participants and Ethics
One-hundred-and-sixteen EAC patients were included in the study.
Esophageal specimens were obtained from patients undergoing
esophagectomy as primary treatment of EAC at The University of
Texas M. D. Anderson Cancer Center (MDACC). Pathologic staging
was done according to the criteria of the American Joint Committee on
Cancer [14]. Histological confirmation of the diagnosis was established
in all patients. Postsurgical surveillance was done every three months
during the first year. Thereafter, it was done every six months for two
additional years, and then yearly. Five to 6 weeks after the completion
of chemoradiation, all patients underwent resection of the esophagus
and regional lymph nodes. The type of surgery was determined by the
location of the primary tumor, condition of the patient, and surgeon’s
preference. The commonly performed procedure was Ivor-Lewis
esophagogastrectomy.
Seventy-five frozen biopsy specimens of tumors and 28 paired
surrounding non-tumor esophageal (NE) tissues endoscopically
obtained before treatment from 2002 through 2007 from 64 EAC
patients were selected from fresh-frozen tissue bank of The
University of Texas M. D. Anderson Cancer Center for microarray
experiments. Furthermore, 15 Barrett’s esophagus frozen biopsy
specimens from Mayo Clinic were included as pre-cancerous tissue
specimens. All samples were collected after obtaining written
informed consent from patients and our study was approved by the
Institutional Review Board (IRB) at the University of Texas MD
Anderson Cancer Center. Clinical data were obtained retrospec-
tively, and table 1 shows the characteristics of the patients with
EAC. To validate the levels of gene expression found by microarray
analysis, quantitative reverse transcription-polymerase chain reac-
tion (qRT-PCR) experiments were performed with formalin-fixed,
paraffin-embedded (FFPE) tissues from an independent EAC
patient group (N=52). Tissue specimens used in qRT-PCR were
obtained retrospectively from the surgical specimens.
Isolation of RNA
Total RNA was extracted from the frozen tissues by using a
mirVanaTM miRNA isolation labeling kit (Ambion Inc., TX,
USA). The total RNA was quantified by using a Nanodrop ND-
1000 spectrophotometer (NanoDrop Technology, DE, USA), and
the integrity of the large RNA fraction was determined with an
ExperionTM (BIO-RAD, CA, USA) as a surrogate for mRNA
quality control. The total RNA samples with adequate RNA
quality index (.7) were used for microarray analysis.
Labeling and Hybridization of mRNA, Scanning, Data
Processing, and Data Analysis
Five-hundred ng of total RNA was used for labeling and
hybridization, according to the manufacturer’s protocols (Illumina
Inc., CA, USA). The hybridized biotinylated cRNA was detected
with 1 mg/ml cyanine 3-streptavidine (GE Healthcare, NJ, USA),
and the bead chips were scanned with an Illumina BeadArray
Reader (Illumina, CA, USA). The microarray data were extracted
with Bead Studio 3.6 (Illumina, CA, USA) and normalized using
the quantile normalization method in the Linear Models for
Microarray Data (LIMMA) package in R language environment
[15]. The expression level of each gene was transformed into a log
2 base before further analysis. Gene network analysis was carried
out using Ingenuity Pathways Analysis software (Ingenuity Systems
Inc., CA, USA). Primary microarray data is available in NCBI’s
Gene Expression Omnibus public database (microarray platform,
GPL6884; microarray data, GSE13898).
Validation of Selected Genes as Prognostic Biomarkers
Using Real-Time RT-PCR
Total RNA was extracted from the FFPE sections following the
manufacturer’s instruction manual (RecoverAllTM Total Nucleic
Acid Isolation; Ambion Inc., TX, USA). Selected genes (SPP1,
SPARC, MMP1, TWIST1, CSPG2, SOX21, DKK3, CD93,
AKR1B10, and LUM) were assayed by using real-time qRT-PCR
with Taqman primers specific to each gene (Applied Biosystems,
CA, USA). Real-time RT-PCR amplification was performed using
the StepOneTM and StepOnePlusTM Real-Time PCR System
(Applied Biosystems., CA, USA). Cycling conditions were 45uC for
10 minutes and 95uC for 10 minutes, followed by 40 cycles of
97uC for 0.02 minutes and 60uC for 0.30 minutes. Relative
amounts of mRNA were calculated from the threshold cycle (CT)
Table 1. Characteristics of patients and tissues.
Variable
Exploration
cohort
Second
cohort
P value
(x2 test) Total
Gender 64 52 0.98 116
Male 59 48 107
Female 5 4 9
Race 0.076
White 58 52 58
Latino 5 0 5
Asian 1 0 1
Age 0.21*
Mean 63.2 60.44
SE 1.5 11.57
Barrett’s# 0.46
+ 20 14 34
2 40 38 78
Smoking{ 0.002
+ 14 25 39
2 50 26 76
Stage{ 0.15
I 2 5 7
II 23 11 34
III 30 29 59
IV 5 7 12
Relapse
20 26 46
Death
21 44 65
*Student t-test.
#Four cases were not available.
{One case was not available.
{Four cases were not available.
doi:10.1371/journal.pone.0015074.t001
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number using expression of cyclophilin A (PPIA) as an endogenous
control. All experiments were duplicated and the values averaged.
Statistical Methods
To select genes that are differentially expressed in two groups of
tissues, we used the class comparison tool in BRB ArrayTools (v
3.6; Biometrics Research Branch, National Cancer Institute, MD,
USA) to perform multiple comparisons of t-statistics with
estimation of false discovery rate (FDR). During statistical analysis,
one of duplicated experiments was removed to avoid redundant
presentation of same sample. Cluster analysis was performed using
the software programs Cluster and Treeview [16]. Associations
between selected genes and prognosis were estimated by applying
Kaplan-Meier plotting and the log-rank test. All statistical analyses
were two-sided and done at a P,0.05 significance level.
Results
Distinct Subtypes of EAC Are Strongly Associated with
Prognosis
We characterized gene expression profiles in 75 EAC and 28 NE
tissue samples from 64 patients.Table 1 lists the clinicopathological
and demographic characteristics of the patients. To estimate the
variance of gene expression of different biopsies from the same
patients, gene expression data were also collected from two different
biopsies of a single patient in 11 randomly selected patients.
An unsupervised hierarchical clustering analysis based on
Pearson correlation coefficients was applied to all tissues from
EAC patients on the basis of similarity in the expression pattern
over all genes. As expected, EAC tissues were well separated from
most of the NE tissues, clearly indicating that global gene
expression fully reflects pathological and biological differences
between NE and EAC (Figure S1). Interestingly, clustering
analysis performed with only EAC tissues revealed three distinct
subgroups with clear differences in overall gene expression
patterns (Figure 1A). As measured in duplicated experiments
with different biopsies from the same patient, the reproducibility of
the data is extremely high. All duplicated experiments resided in
nearest neighbors after clustering, strongly suggesting that the
variance among experiments and biopsies was negligible. There-
fore, most of the difference in gene expression largely reflected
biological, as well as clinical, differences among the EAC cases.
Having three distinctive subclasses of EAC that may reflect
clinical heterogeneity, we next examined the association between
the clusters and clinical data. Kaplan-Meier survival curves
indicated poorer prognosis of patients in cluster B (Figure 1B).
Recurrence free survival (RFS) was significantly worse in cluster B
patients than those in clusters A and C (P=0.0036, by log-rank
test). In addition, the mean overall survival (OS) of cluster B
patients was much shorter (,13 month) than that of the rest of the
patients. Thus, the molecular differences between the three
subclasses of EAC that we identified were well associated with a
remarkable difference in the clinical outcomes of these patients.
Gene Expression Signature Is Strongly Associated with
Prognosis
Since the most striking feature of the unsupervised analysis of
the expression profiles was the strong association with prognosis
and the presence of three subgroups of EAC, we next applied
statistical analysis methods to uncover the genes whose expression
patterns are best associated with EAC subgroup clustering and
prognosis. We first sought to find gene sets that are differentially
expressed in the three EAC subgroups (cluster A, B, and C). We
generated two different gene lists by applying two-sample t-tests
(P,0.002). Genes were further selected to have 1.5-fold differences
between the groups compared in the t-tests. Gene List X (2,344
gene features) represents the genes that were differentially
expressed between clusters A and B, whereas gene List Y (1489
gene features) represents the genes that were differentially
expressed between clusters B and C (Figure 2A). When two
gene lists were compared, 3 different sets were observed: X not Y
(1,892), X and Y (452), and Y not X (1,037). Genes in the X and Y
category displayed specific gene expression patterns relatively
enriched in cluster B patients. Because patients in cluster B showed
poorer prognosis, we further investigated gene expression data in
the X and Y gene list (Figure 2B).
Having found a gene expression pattern well reflecting prognosis
of EAC patients, we next tried to uncover gene networks that might
be enriched in these genes. Gene network analysis using
IngenuityTM Pathway Analysis (IPA) (Ingenuity Systems, CA,
USA) was applied to the genes and their expression patterns. This
analysis revealed a series of putative networks, of which the 20 with
the highest scores are listed in Table S1. For example, functional
connectivity of the top network (network#1) revealed a strong over-
representation of NF-kB (Figure 3). Although the expression of NF-
kB was not altered, the expression levels of many downstream target
genes of NF-kB were up-modulated in patients in cluster B, strongly
indicating that transcriptional activity of NF-kB is high in cluster B
and might be responsible for the poorer prognosis of these patients.
Exploration of Candidate Biomarkers
Regardless of strong association of the expression signature with
prognosis, the large number of genes in the signature would
hamper its clinical usefulness. To overcome this limitation, we next
tried to identify a small number of genes whose expression patterns
can reliably predict OS or RFS in EAC patients. Out of the 452
genes previously identified, we first selected the genes whose
expression levels significantly differed in magnitude ($4-fold)
between patients in cluster B and those in clusters A and C. In
order to minimize over-representation of particular gene networks
or pathways in selected prognostic markers, we limited to two the
maximum number of genes per predicted gene network (Table
S1). Ten genes met these criteria, namely AKR1B10, CD93,
CSPG2, DKK3, LUM, MMP1, SOX21, SPP1, SPARC, and TWIST1.
Using hazard ratios from the univariate Cox regression analysis as
indicators of survival, AKR1B10 and SOX21 are protective genes
(associated with a hazard ratio of less than 1) and the others are
risk genes (associated with a hazard ratio of more than1).
Considering the 10 selected genes as representative prognostic
molecular markers, we tested whether expression of the genes or
their subsets could predict the duration of survival in an
independent cohort. Before applying qRT-PCR in an independent
cohort, we assessed the reliability of gene expression measurements
in our microarray study by comparing them with those obtained
using qRT-PCR in replicate samples. We isolated total RNA from
FFPE tissues from 52 EAC patients and applied qRT-PCR with the
use of specific TaqManTM probes and primer sets to the total RNA
in order to measure gene expression. We first assessed the
prognostic relevance of expression by applying Kaplan-Meier
plotting and the log-rank test after dichotomizing patients. The
median expression level of each gene was chosen as the cut-off value
to ensure equal numbers of patients in poor and better prognosis
groups. Expression of SPARC and SPP1 was significantly associated
(P= 0.05, by log-rank test) with OS of EAC patients in the
validation cohort (Figure 4A & B). We tested whether combined
expression patterns of two genes can improve the significance of
association. When patients were dichotomized by averaged
expression values of SPARC and SPP1, the association between
Prognostic Novel Biomarkers of EAC
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the two genes and OS was highly significant (P= 0.0007, by log-
rank test), strongly suggesting that the prognostic association of the
two genes in EAC is synergistic (Figure 4C). However, prognostic
association of the rest of genes was not significant (data not shown).
Prognostic Utility of Gene Expression Signature in EAC
To evaluate the prognostic relevance of our newly discovered
gene expression signatures, we applied univariate and multivariate
analyses of the signatures using known clinical and pathological
risk factors for EAC progression. In agreement with previous
reports [2,8], we found several tumor characteristics associated
with OS using univariate Cox proportional hazards analysis
(Table 2). In addition, multivariate analyses that included all
relevant pathological variables revealed that gene signature was
independent prognostic markers for OS of EAC patients.
Therefore, our findings suggest that our gene signature retains
its prognostic relevance, even after the ‘‘classical’’ pathological
prognostic features have been taken into account. Moreover, the
gene expression signature was revealed independently of the
clinicopathological features of EAC tumors, indicating that the
potential clinical utility of the signature might come from a better
mechanistic understanding of EAC progression.
Discussion
Previous genome-wide studies on various cancers strongly
support the notion that biological difference reflected in gene
expression profiles of tumors may dictate the prognosis of cancer
patients [9–13]. In the present study, we applied systems-level
characterization of EAC transcriptome to address molecular
heterogeneity of EAC and to extract a gene expression signature
that can subdivide EAC patients to homogeneous groups with
significant clinical and biological difference. In an attempt to
address the molecular heterogeneity of EAC, we first applied
unsupervised analysis of gene expression data, which revealed three
subgroups of EAC. Significant association of the three subgroups
with prognosis and distinct gene expression patterns within each
subgroup led us to hypothesize that the unique gene expression
patterns of each subgroup may reflect biological as well as clinical
heterogeneity of EAC. For example, many of the selected genes
whose expression patterns are associated with cluster B, the worst
prognosis subgroup, are well known to be involved in metastasis/
invasion (i.e., SPP1, MMP1, MMP2, MMP3, TIMP1, CDH11, and
TWIST1) and proliferation (i.e., CDK4 and MCM2). An intriguing
feature among our 452 potential prognostic gene expression
signatures is that around 80% of the genes showed a relatively
high level of expression in cluster B patients when compared with
the rest of the patients, indicating that gain, rather than loss, of gene
activity may have more influence on the prognosis of EAC.
However, application of gene expression profiles to clinical
practice is very challenging due largely to the difficulty to get fresh-
frozen tissues from patients for microarray experiments and the
complexity of data analysis with large number of genes. Therefore,
we sought to develop methods that use quantitative real-time RT-
PCR and RNA from easily accessible paraffin embedded specimen
Figure 1. Hierarchical clustering analysis. (A) Hierarchical cluster-
ing of genes from 75 EAC tissues. Genes with an expression ratio that
was at least twofold different relative to reference in at least 8 tissues
were selected for hierarchical analysis (6,802 gene features). The data
are presented in matrix format, with rows representing the individual
gene and columns representing each tissue. Each cell in the matrix
represents the expression level of a gene feature in an individual tissue.
Red and green reflect high and low expression levels, respectively, as
indicated in the scale bar (log 2 transformed scale). Duplicated biopsies
from the same patients were highlighted in colors in dendrogram.
(B) Kaplan-Meier plot of disease-free survival of EAC patients grouped
on the basis of gene expression profiling.
doi:10.1371/journal.pone.0015074.g001
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from patients. The robustness of the prognostic gene expression
signature was validated in an independent cohort using the
reduced gene set. Out of 10 prognostic markers tested, two genes
(SPARC and SPP1) were significantly associated when gene
expression patterns were measured by qRT-PCR in the
independent cohort. SPARC is a matricellular protein that
modulates cell adhesion and growth and modulates cell-matrix
interactions by binding to the extracellular matrix [17]. High levels
of SPARC are often associated with metastastic tumors [18–20].
In fact, SPARC has been proposed as a diagnostic marker of
Figure 2. Cross comparison of gene lists from two independent statistical tests. (A) Venn Diagram of genes differentially expressed. The
blue circle (gene list X) represents genes differentially expressed between cluster A and B. The red circle (gene list Y) represents genes differentially
expressed between cluster B and C. Four-hundred-fifty-two genes were shared by the two gene lists. We applied a cut-off P-value of less than 0.002
to retain genes whose expression is significantly different between the two groups of tissues examined. (B) Heat map of gene expression patterns.
Blue and pink bars on the left side of the heat map represent each selected genes. Colored bars at the top of the heat map represent the tissues
indicated. Expression of genes in the X not Y category was dramatically different between clusters A and B as well as between clusters A and C, but
almost no differences were observed between clusters B and C, signifying a unique gene expression signature that distinguishes patients in cluster A
from the rest of the patients.
doi:10.1371/journal.pone.0015074.g002
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invasive meningiomas [21]. The expression of SPARC is correlated
significantly with MMP2 mRNA expression in esophageal tumor
tissue specimens, and high SPARC expression was found to be
correlated significantly with lymph node metastasis and poor
patient prognosis [22]. SPP1, a secreted glycoprotein, also
regulates cell adhesion and is well associated with metastasis in
various cancers [23,24]. In prostate cancer, elevated plasma SPP1
levels have been correlated with bone metastasis and poorer
survival [25]. Thus, our findings concur with previous reports of
these genes in other cancers.
Figure 3. Gene networks from IngenuityTM Pathway Analysis. Global networks of inter-connection among genes and expression patterns of
genes in network #1 in Appendix Table 1. Red and green colors in each shape indicate up- or down-regulation of expression in cluster B when
compared with cluster A and C. Genes in gray color are not in the list but associated with the regulated genes. Each line and arrow represents
functional and physical interaction and direction of regulation demonstrated in the literature. Genes inter-connected with NF-kB are highlighted in
blue lines.
doi:10.1371/journal.pone.0015074.g003
Figure 4. Kaplan-Meier plots of overall survival for EAC patients. (A) Overall survival by SPARC status in 52 patients. (B) Overall survival by
SPP1 status in 52 patients. (C) Overall survival by SPARC+SPP1 in 52 patients.
doi:10.1371/journal.pone.0015074.g004
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Our data indicate that the prognostic gene expression signatures
are present at the time of diagnosis. Therefore, the use of gene
expression profiling promises to improve the molecular classifica-
tion of EAC patients by adding to the existing classifications. Since
our current method only use a very small amount of paraffin
embedded tissues that are routinely acquired during diagnosis, we
could potentially identify EAC patients with higher risk even
before starting the treatment. Although our two-gene signature is
examined in two independent cohort groups, robustness of
signature should be further validated in larger cohort. Prospective
multi-center studies would be ideal. Molecular stratification of
EAC patients into homogeneous subgroups may improve the
application of currently available treatments and provide oppor-
tunities for the development of new treatment modalities.
Supporting Information
Figure S1 Hierarchical clustering analysis of gene
expression data from esophageal tissues. Hierarchical
clustering was applied to gene expression data from 75 EAC and
28 non-tumor esophageal tissues. Genes with an expression level
that has at least 2-fold difference relative to median value across
tissues in at least 18 tissues were selected for hierarchical clustering
analysis (3,296 gene features). The data are presented in matrix
format in which rows represent individual gene and columns
represent each tissue. Each cell in the matrix represents the
expression level of a gene feature in an individual tissue. The red
and green color in cells reflect relative high and low expression
levels respectively as indicated in the scale bar (log2 transformed
scale).
(PDF)
Table S1 Top 20 list of gene networks from Ingenui-
tyTM Pathway Analysis.
(PDF)
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